Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals, Inc. (TARS)
:TARS
TARS Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TARS Stock 12 Month Forecast
Average Price Target
$83.40
▲(23.45% Upside)
| Highest Price Target$88.00 | Average Price Target$83.40 | Lowest Price Target$75.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$72→$88
Buy
30.25%
Upside
Reiterated
10/20/25
Promising Growth and Market Penetration of XDEMVY Drives Buy Rating and Increased Price TargetValuation and Risks. We reiterate our Buy rating and have raised our price target up from $72, to $88 per share. Our price target of $88 per share are based on an equally-weighted composite of: (a) $78.48 per share, as a 25x multiple of taxed and diluted 2036 EPS of $12.04 discounted back to and (b) an NPV discounted cash flow between 2025-2036 of $97.38 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of an early commercial and developmental-stage biopharmaceutical company.
Bank of America Securities
$80→$85
Buy
25.81%
Upside
Reiterated
10/09/25
William Blair
―
Buy
―
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)We believe this rapid adoption supports the effectiveness of the company’s efforts to drive broader prescribing, but also indicates the positive experience that doctors have had with Xdemvy, as we believe they would be unlikely to broaden their prescribing if they had been unsatisfied with the results of the product to date. While this broad use is an encouraging sign and provides some validation of the company’s estimated target market of 9 million patients, management noted that most ECPs are still in the very early stages of expanding their prescribing across patient segments, having prescribed Xdemvy to only a handful of patients in some segments.
Oppenheimer
$75
Buy
11.01%
Upside
Reiterated
08/13/25
LifeSci Capital
$85
Buy
25.81%
Upside
Reiterated
08/07/25
Guggenheim
$84
Buy
24.33%
Upside
Reiterated
08/06/25
Goldman Sachs
$44
Hold
-34.87%
Downside
Reiterated
07/15/25
Jefferies
$54→$58
Buy
-14.15%
Downside
Reiterated
03/06/25
Barclays
$62→$60
Buy
-11.19%
Downside
Reiterated
03/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$72→$88
Buy
30.25%
Upside
Reiterated
10/20/25
Promising Growth and Market Penetration of XDEMVY Drives Buy Rating and Increased Price TargetValuation and Risks. We reiterate our Buy rating and have raised our price target up from $72, to $88 per share. Our price target of $88 per share are based on an equally-weighted composite of: (a) $78.48 per share, as a 25x multiple of taxed and diluted 2036 EPS of $12.04 discounted back to and (b) an NPV discounted cash flow between 2025-2036 of $97.38 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of an early commercial and developmental-stage biopharmaceutical company.
Bank of America Securities
$80→$85
Buy
25.81%
Upside
Reiterated
10/09/25
William Blair
―
Buy
―
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)We believe this rapid adoption supports the effectiveness of the company’s efforts to drive broader prescribing, but also indicates the positive experience that doctors have had with Xdemvy, as we believe they would be unlikely to broaden their prescribing if they had been unsatisfied with the results of the product to date. While this broad use is an encouraging sign and provides some validation of the company’s estimated target market of 9 million patients, management noted that most ECPs are still in the very early stages of expanding their prescribing across patient segments, having prescribed Xdemvy to only a handful of patients in some segments.
Oppenheimer
$75
Buy
11.01%
Upside
Reiterated
08/13/25
LifeSci Capital
$85
Buy
25.81%
Upside
Reiterated
08/07/25
Guggenheim
$84
Buy
24.33%
Upside
Reiterated
08/06/25
Goldman Sachs
$44
Hold
-34.87%
Downside
Reiterated
07/15/25
Jefferies
$54→$58
Buy
-14.15%
Downside
Reiterated
03/06/25
Barclays
$62→$60
Buy
-11.19%
Downside
Reiterated
03/06/25
Best Analysts Covering Tarsus Pharmaceuticals
1 Month
xxx
Success Rate
11/15 ratings generated profit
Average Return
+8.63%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +8.63% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
Average Return
+13.94%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +13.94% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+75.51%
reiterated a buy rating 3 months ago
Copying Eddie Hickman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +75.51% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
Average Return
+125.11%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +125.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TARS Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
5
7
7
6
4
Buy
2
2
3
4
6
Hold
3
3
6
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
12
16
15
14
Each month's total comprises the sum of three months' worth of ratings.
TARS Financial Forecast
TARS Stock Forecast FAQ
What is TARS’s average 12-month price target, according to analysts?
Based on analyst ratings, Tarsus Pharmaceuticals, Inc.’s 12-month average price target is 83.40.
What is TARS’s upside potential, based on the analysts’ average price target?
Tarsus Pharmaceuticals, Inc. has 23.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TARS a Buy, Sell or Hold?
Tarsus Pharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tarsus Pharmaceuticals, Inc.’s price target?
The average price target for Tarsus Pharmaceuticals, Inc. is 83.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $88.00 ,the lowest forecast is $75.00. The average price target represents 23.45% Increase from the current price of $67.56.
The highest analyst price target is $88.00 ,the lowest forecast is $75.00. The average price target represents 23.45% Increase from the current price of $67.56.
What do analysts say about Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of TARS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.